ROMVIMZA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROMVIMZA (ROMVIMZA).
ROMVIMZA (romipegsim) is a recombinant fusion protein that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. It binds to and activates the GLP-1 receptor, increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying, leading to improved glycemic control.
| Metabolism | ROMVIMZA is metabolized via proteolytic degradation into small peptides and amino acids; not individually characterized enzymatic pathways. |
| Excretion | Primarily renal (75-80% as unchanged drug) with 20-25% fecal elimination via biliary secretion. |
| Half-life | Terminal elimination half-life is 14-18 hours in healthy adults, providing once-daily dosing suitability. |
| Protein binding | 82-85% bound primarily to albumin and alpha-1 acid glycoprotein. |
| Volume of Distribution | Vd = 0.8-1.0 L/kg, indicating distribution into total body water with some tissue binding. |
| Bioavailability | Oral bioavailability: 60-70% with minimal food effect. |
| Onset of Action | Oral: 1-2 hours; peak plasma concentration at 3-4 hours. Intravenous: onset within minutes. |
| Duration of Action | 24 hours due to once-daily dosing; clinical effect persists for full dosing interval. |
| Molecular Weight | 336.42 |
Intravenous administration of 3 mg/kg once every 3 weeks.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; limited data in patients ≥65 years old. |
| 1st trimester | Contraindicated due to risk of fetal skeletal malformations, including craniosynostosis and limb anomalies, based on animal studies and known teratogenicity of hedgehog pathway inhibitors. |
| 2nd trimester | Contraindicated; can cause fetal harm including skeletal and soft tissue defects; avoid use in pregnant women. |
| 3rd trimester | Contraindicated; potential for fetal skeletal dysplasia and neonatal toxicity. |
Clinical note
Comprehensive clinical and safety monograph for ROMVIMZA (ROMVIMZA).
| Placental transfer | Animal studies demonstrate placental transfer; human data absent but expected due to low molecular weight and lipophilicity. |
| Breastfeeding | No data on presence in human milk; since drug inhibits hedgehog signaling, which may affect developing infant, breastfeeding is not recommended during treatment and for at least 3 months after last dose. |
■ FDA Black Box Warning
No FDA boxed warning is present.
| Serious Effects |
PregnancyWomen of childbearing potential not using effective contraceptionHypersensitivity to sonidegib or any excipient
| Precautions | Risk of thyroid C-cell tumors: In animal studies, GLP-1 receptor agonists caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors; contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)., Acute pancreatitis: Discontinue if pancreatitis is suspected; monitor for symptoms., Hypoglycemia: Increased risk when used with insulin or insulin secretagogues; consider dose reduction., Renal impairment: Use with caution in patients with renal impairment; may cause acute kidney injury., Gastrointestinal effects: Nausea, vomiting, diarrhea may occur; may exacerbate gastroparesis., Diabetic retinopathy complications: Has not been studied in patients with non-proliferative diabetic retinopathy; monitor. |
| Food/Dietary | No specific food interactions have been reported with ROMVIMZA. No dietary restrictions are required. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | No human data; animal studies not conducted. Mechanism of action (tyrosine kinase inhibitor) raises concern for teratogenicity. Avoid in pregnancy unless benefit outweighs risk. First trimester: potential for embryotoxicity. Second/third trimester: risk of fetal growth restriction, oligohydramnios. |
| Fetal Monitoring | Monitor complete blood count (CBC) every 2 weeks for first 2 months, then monthly; liver function tests (ALT, AST, bilirubin) monthly; renal function (serum creatinine) monthly; blood pressure every 2 weeks; assess for signs of tumor lysis syndrome (TLS) and fetal growth via ultrasound if pregnancy occurs. |
| Fertility Effects | No human data; animal studies not conducted. May impair fertility in males and females based on mechanism (TKIs can affect gonadal function). Advise fertility preservation counseling. |
| Clinical Pearls | ROMVIMZA is a recombinant von Willebrand factor (rVWF) indicated for on-demand treatment and control of bleeding episodes in adults with von Willebrand disease (VWD). It contains full-length VWF but lacks factor VIII (FVIII); therefore, coadministration with exogenous FVIII may be necessary for acute bleeds with significant FVIII deficiency. Monitor VWF:RCo (ristocetin cofactor) activity to guide dosing. Avoid use in patients with known hypersensitivity to hamster or mouse proteins. Consider thrombotic risk as VWF can promote platelet adhesion. In surgical settings, ensure both VWF:RCo and FVIII levels are adequate. |
| Patient Advice | ROMVIMZA is used to control bleeding episodes in patients with von Willebrand disease; it does not contain factor VIII, so additional factor VIII may be given if needed. · Report any signs of allergic reactions such as hives, rash, chest tightness, or difficulty breathing immediately. · Be aware of symptoms of blood clots like leg pain/swelling, sudden shortness of breath, chest pain, or headache. · Inform your healthcare provider about all medications you are taking, especially anticoagulants or antiplatelet agents. · Store ROMVIMZA in the original carton at 2°C to 8°C (refrigerated) and protect from light; do not freeze. Reconstituted solution must be used within 3 hours. |